The latest leukaemia news
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive cancer which is lethal to 15% of…
The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed…
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown…
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the…
In patients with chronic lymphocytic leukaemia (CLL), the rate of disease growth is apt to…
Nearly 90 per cent of children with acute lymphoblastic leukaemia (ALL) survive, yet the same…
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD…
11,000 people are predicted to die from acute myeloid leukaemia (AML) in 2019, according to…
Only about one in four people diagnosed with acute myelogenous leukaemia (AML) survive five years…
11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019, according to…